In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.Read More
Breast cancer is the most commonly diagnosed cancer in the United States. In 2018, 266,120 women and 2,550 men are expected to receive the news that they have the disease, according to National Cancer Institute data.
Inherited mutations in the BRCA1 and BRCA2 genes account for between 5 percent and 10 percent of breast cancers in U.S. women and between 5 percent and 20 percent of breast cancers in U.S. men. For women who undergo genetic testing and learn that they have inherited a BRCA1/2 mutation before they receive a breast cancer diagnosis there are ways to reduce their risk of going on to develop the disease.Read More
In a study published in the AACR’s journal Clinical Cancer Research, a team of scientists from the University of Pittsburgh discuss yet another area of cancer research where artificial intelligence (AI) can potentially solve a decades-long problem: false-positive results and high patient recall rates from breast cancer screening mammography.Read More
The 30th Anniversary AACR Special Conference Convergence: Artificial Intelligence, Big Data, and Prediction in Cancer is focusing on a relatively new interdisciplinary field that seeks to further cancer research through the use of mathematics and computation, among other disciplines.
We had the opportunity to speak with both co-chairs about convergence and several areas of interest that will be discussed at the upcoming meeting, to be held Oct. 14-17 in Newport, Rhode Island.Read More
On Sunday, Margaret Foti, PhD, MD (hc), chief executive officer of the AACR, met with the president of Israel, Reuven Rivlin, at his residence in Jerusalem.
Foti has had a long, fruitful relationship with the Israeli cancer community. Her meeting with Rivlin and First Lady Nechama Rivlin was coordinated by longtime friend and colleague Miri Ziv, the Director General of the Israel Cancer Association.Read More
Last week saw a flurry of new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) for treating several types of cancer. On Monday, Sept. 24, the agency approved the molecularly targeted therapeutic duvelisib (Copiktra) for treating certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and for treating certain patients with follicular lymphoma. On Thursday, Sept. 27, it approved another molecularly targeted therapeutic—dacomitinib (Vizimpro)—for treating certain patients with non–small cell lung cancer (NSCLC). Then, on Friday, Sept. 28, it approved the immunotherapeutic cemiplimab-rwlc (Libtayo) for treating certain patients with cutaneous squamous cell carcinoma.Read More
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the bone marrow and the blood that develops in either B lymphocytes or T lymphocytes. While ALL can occur in both …Read More
On Monday, James P. Allison, PhD, a Fellow of the AACR Academy and a past member of the AACR’s Board of Directors, won the 2018 Nobel Prize in Physiology or Medicine for his pioneering work in cancer immunotherapy.Read More
Editor’s note: Progress and Promise Against Cancer is the AACR’s initiative to educate the public about cancer and cancer research. This event is part of a live and online event …Read More
As a monthly feature on this blog, we spotlight the 10 articles selected by our editors from each journal issue published by the American Association of Cancer Research (AACR). These journals feature original articles spanning the continuum of cancer research, from basic science discoveries to patient care.Read More
Today, September 24, 2018, is World Cancer Research Day. The American Association for Cancer Research (AACR) is proud to join cancer organizations, associations, and researchers from around the world in supporting this global initiative that aims to raise awareness about the importance of cancer research for saving lives.Read More